|Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction.|
|PMID: 19350119 Owner: NLM Status: MEDLINE|
|Fibrinolysis for acute ST-segment elevation MI achieves early recanalisation of the infarct artery in approximately 60% of cases. The aim of the study was to determine whether failure to achieve recanalisation was associated with differences in haemostasis biomarkers compared to patients with successful fibrinolysis. Fourty-three patients were prospectively enrolled in a case-control study. All patients had received tenecteplase (TNK-tPA) together with aspirin (500 mg) and heparin (5,000 IU). Emergency angiography within 90 minutes of bolus TNK-tPA identified 13 TIMI 0-2 patients (cases) and 30 TIMI 3 patients (controls). Blood samples were collected before angiography to determine tissue factor activity associated with microparticles (TF-MP); soluble platelet glycoprotein V (sGPV) and thrombin-antithrombin complexes (TAT) as markers of thrombin generation; tissue plasminogen activator (endogenous tPA+ TNK-tPA), plasminogen activator inhibitor (PAI-1) and plasmin-antiplasmin complexes (PAP) as markers of plasmin generation. The baseline characteristics of the two patients' groups were similar with respect to sex, age, and risks factors. Cases differed from controls by higher TF-MP levels (1.9 [1-13] vs. 1 [0.6-1.3] pM), sGPV (67 [51-126] vs. (48 [39-72] ng/ml), p = 0.039 and TAT (10 [4-37.5] vs. 4 [2.9-7.2] ng/ml), p = 0.035. TAT correlated with TF-MP (r = 0.51, p = 0.0064) and sGPV (r = 0.51, p = 0.0018). No significant difference was observed in tPA or PAI-1 levels. PAP were lower in cases (18.83 [14.83-40.43] mug/ml) than in controls (35.83 [27.9-43.94] mug/ml), p = 0.045. In conclusion, fibrinolysis failure in AMI is characterised by a higher procoagulant state associated with TF-MP and a lower plasmin generation.|
|Marie-Geneviève Huisse; Nadine Ajzenberg; Laurent Feldman; Marie-Claude Guillin; Philippe Gabriel Steg|
Related Documents :
|15198879 - Evaluation of von willebrand factor-cleaving protease activity in patients with thrombo...
21178849 - Progression of cervical instabilities in rheumatoid arthritis (ra) -a prospective cohor...
1728719 - Abnormalities in von willebrand factor and antithrombin iii after cardiopulmonary bypas...
2267279 - Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor...
2837699 - Angiotensin converting enzyme inhibitors and cough.
7741509 - Activated recombinant factor vii in the treatment of retroperitoneal haemorrhage in a p...
635479 - Treatment of anginose infectious mononucleosis with metronidazole.
23717059 - Korean red ginseng powder in the treatment of melasma: an uncontrolled observational st...
12578919 - Hippocampal atrophy and t2-weighted signal changes in familial mesial temporal lobe epi...
|Type: Journal Article; Research Support, Non-U.S. Gov't|
|Title: Thrombosis and haemostasis Volume: 101 ISSN: 0340-6245 ISO Abbreviation: Thromb. Haemost. Publication Date: 2009 Apr|
|Created Date: 2009-04-07 Completed Date: 2009-10-30 Revised Date: 2009-11-19|
Medline Journal Info:
|Nlm Unique ID: 7608063 Medline TA: Thromb Haemost Country: Germany|
|Languages: eng Pagination: 734-40 Citation Subset: IM|
|Department of Haematology, AP-HP, Hôpital Bichat, Paris, France. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
Aged, 80 and over
Angioplasty, Transluminal, Percutaneous Coronary
Anticoagulants / administration & dosage
Aspirin / administration & dosage
Biological Markers / blood
Cell-Derived Microparticles / drug effects*, metabolism
Drug Administration Schedule
Drug Therapy, Combination
Fibrinolysin / metabolism
Fibrinolytic Agents / administration & dosage*
Hemostasis / drug effects*
Heparin / administration & dosage
Myocardial Infarction / blood, drug therapy*, physiopathology, radiography
Platelet Aggregation Inhibitors / administration & dosage
Thrombin / metabolism*
Thromboplastin / metabolism*
Tissue Plasminogen Activator / administration & dosage*
|0/Anticoagulants; 0/Biological Markers; 0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 9005-49-6/Heparin; 9035-58-9/Thromboplastin; EC 3.4.21.-/TNK-tissue plasminogen activator; EC 188.8.131.52/Thrombin; EC 184.108.40.206/Tissue Plasminogen Activator; EC 220.127.116.11/Fibrinolysin|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Protection of vascular barrier integrity by activated protein C in murine models depends on protease...
Next Document: Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer.